Patent foramen ovale (PFO) is an opening in the upper chambers of the heart due to a flap of tissue that failed to close normally after a baby is born. There is no known cause.
PFO: what you should know
- Treatment is not necessary in most cases. Infants born with PFO and no other heart conditions are not considered to have an abnormal heart condition.
- Older adults with PFOs may have a higher risk of a certain type of stroke called paradoxical thromboembolic stroke.
- There are usually no symptoms associated with PFO.
Care for patent foramen ovale at Rush
An imaging test called an echocardiogram can be used to diagnose a PFO.
The condition, however, doesn't require treatment unless other heart problems exist or if the patient has had recurrent, unexplained strokes. For patients with stroke and PFO, Rush is one of only a few centers in the U.S. conducting research on closing such defects.
If treatment is required, a highly trained heart expert at Rush will likely close the PFO using a procedure called cardiac catheterization.
Catheterization avoids the need for the chest to be opened. A thin, flexible tube called a catheter is threaded to the heart through a blood vessel in the arm, upper thigh or neck.
Rush is a Center of Excellence for PFO closure procedures, offering the most advanced treatments, including the Amplatzer PFO occluder and Gore Cardioform septal occluder devices.
And Rush is the first hospital in Chicago to offer a new technology called Noble Stitch that enables cardiologists to close a PFO using a single stitch.
Rush interventional cardiologists are also leaders in clinical trials looking at the relationship between PFO and stroke in adults. Read the story of Janet Cunning, who had a PFO closure procedure at Rush after a scary series of health crises.
Why choose Rush for patent foramen ovale care
- Experts at the Rush Pediatric Congenital Heart Disease Program provide personalized, coordinated treatment for heart problems that are present at birth.
- Pediatric cardiologists and interventional cardiologists at Rush are leaders in clinical trials of new therapies for PFO and other congenital heart defects. This means patients at Rush often have access to treatments before they are widely available.